ヒトマイクロバイオーム市場 : 2029年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2023年5月

ヒトマイクロバイオーム市場 : 製品(医薬品、プロバイオティクス、プレバイオティクス)、用途(治療薬、診断薬)、疾患(がん、胃腸、感染症)、種類(ペプチド、LBP製品、FMT) – 2029年までの世界予測
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) – Global Forecast to 2029

ページ数183
図表数195
種別英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The human microbiome market is projected to reach USD 1.7 billion by 2029 from USD 0.3 billion in 2023, at a CAGR of 36.1% during the forecast period. The key factors driving the growth of the human microbiome market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.
The human microbiome market has been segmented based on product, type, application, disease, and region.

ヒトマイクロバイオーム市場 : 製品(医薬品、プロバイオティクス、プレバイオティクス)、用途(治療薬、診断薬)、疾患(がん、胃腸、感染症)、種類(ペプチド、LBP製品、FMT) - 2029年までの世界予測 Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

“By application, the therapeutics segment accounted for the largest share of the human microbiome market”
Based on application, the human microbiome market is categorized into therapeutics, and diagnostics. The therapeutics segment dominated the market in 2023, owing to the increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine.

ヒトマイクロバイオーム市場 : 製品(医薬品、プロバイオティクス、プレバイオティクス)、用途(治療薬、診断薬)、疾患(がん、胃腸、感染症)、種類(ペプチド、LBP製品、FMT) - 2029年までの世界予測 Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

“By disease, infectious diseases segment accounted for the largest share in the human microbiome market”
Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. In 2023, the infectious diseases segment accounted for a larger share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the role of the microbiome in human health and the development of advanced sequencing and bioinformatics techniques are paving the way for the discovery and characterization of novel microbiome-based therapeutics for the prevention and treatment of infectious diseases.

ヒトマイクロバイオーム市場 : 製品(医薬品、プロバイオティクス、プレバイオティクス)、用途(治療薬、診断薬)、疾患(がん、胃腸、感染症)、種類(ペプチド、LBP製品、FMT) - 2029年までの世界予測 Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

“North America: the largest share of the human microbiome market”
North America accounted for the largest share of the human microbiome market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in microbiome research. The presence of top academic institutions, research hospitals, and private companies in North America with dedicated microbiome research programs and expertise has contributed to the growth of the human microbiome market.

ヒトマイクロバイオーム市場 : 製品(医薬品、プロバイオティクス、プレバイオティクス)、用途(治療薬、診断薬)、疾患(がん、胃腸、感染症)、種類(ペプチド、LBP製品、FMT) - 2029年までの世界予測 Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

“Asia Pacific: The fastest-growing region in the human microbiome market.”
The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific human microbiome market is the region’s large and rapidly aging population.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 60% and Demand Side 40%
• By Designation: Executives – 40%, Research Scientists- 30%, and Managers – 30%
• By Country: North America- 22%, Europe- 42%, Asia Pacific- 11%, Rest of the World- 25%

Prominent Players
• Seres Therapeutics, Inc. (US)
• Enterome (France)
• 4D pharma plc (UK)
• International Flavors & Fragrances Inc. (US)
• OptiBiotix Health Plc (UK)
• Ferring Pharmaceuticals (Switzerland)
• Synlogic, Inc. (US)
• Second Genome, Inc. (US)
• Vedanta Biosciences, Inc. (US)
• YSOPIA Bioscience (France)
• FlightPath Biosciences, Inc. (US)
• Finch Therapeutics Group, Inc. (US)
• AOBiome Therapeutics (US)
• BioGaia (Sweden)
• Quantbiome, Inc. (dba Ombre) (US)
• Viome Life Sciences, Inc. (US)
• BIOHM Health (US)
• DayTwo (US)
• Atlas Biomed (UK)
• Bione Ventures Private Limited (India)
• Luxia Scientific (France)
• Metabiomics (US)
• Sun Genomics (US)
• Seed Health (US)
• Gnubiotics Sciences (Switzerland)

ヒトマイクロバイオーム市場 : 製品(医薬品、プロバイオティクス、プレバイオティクス)、用途(治療薬、診断薬)、疾患(がん、胃腸、感染症)、種類(ペプチド、LBP製品、FMT) - 2029年までの世界予測 Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029
Research Coverage:
This report provides a detailed picture of the human microbiome market. It aims at estimating the size and future growth potential of the market across different segments, such as the product (drugs, diagnostics tests, probiotics, prebiotics, and other products), application (therapeutic, and diagnostics), disease (infectious diseases, gastrointestinal diseases, endocrine & metabolic diseases, cancer, and other diseases), type (Bacterial consortia transplantation (BCT)/ fecal microbiota transplantation(FMT), peptides, live biotherapeutic products, and other types), and region (North America, Europe, Asia Pacific, and Rest of the World). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall human microbiome market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers
• Analysis of key drivers (collaborative efforts between microbiome industry and academia for microbiome research, surging demand for personalized medicine, and rising awareness about importance of human microbiome), restraints (adverse impact of complex regulatory policies on commercialization of microbiomes), opportunities (increased collaboration of key players and small innovative companies collaborating to work on new microbiome technologies, and advancements in sequencing and bioinformatics), and challenges (low patient adoption rate of microbiome-based therapies, and complexities involved in development of microbiome therapies) influencing the growth of the human microbiome market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the human microbiome market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the human microbiome market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human microbiome market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), and OptiBiotix Health Plc (UK) among others in the human microbiome market strategies. The report also helps stakeholders understand the pulse of the animal research model market and provides them information on key market drivers, restraints, challenges and opportunities.


目次

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.3 STUDY SCOPE 26
1.4 YEARS CONSIDERED 26
1.5 CURRENCY 27
1.6 RESEARCH LIMITATIONS 27
1.7 STAKEHOLDERS 27
1.7.1 RECESSION IMPACT 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 1 HUMAN MICROBIOME MARKET: RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 29
2.1.2 PRIMARY DATA 29
FIGURE 2 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES 30
2.2 MARKET ESTIMATION METHODOLOGY 30
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 31
FIGURE 4 HUMAN MICROBIOME MARKET SIZE, 2023 (USD MILLION) 32
FIGURE 5 HUMAN MICROBIOME MARKET: FINAL CAGR PROJECTIONS (2023−2029) 32
FIGURE 6 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 33
2.3 MARKET DATA ESTIMATION AND TRIANGULATION 34
2.3.1 DATA TRIANGULATION 34
FIGURE 7 DATA TRIANGULATION METHODOLOGY 34
2.4 INDUSTRY INSIGHTS 35
2.5 RESEARCH ASSUMPTIONS 35
2.6 HUMAN MICROBIOME MARKET: GLOBAL RECESSION IMPACT 36
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 36
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 36
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 36
3 EXECUTIVE SUMMARY 38
FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION) 38
FIGURE 9 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION) 39

FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION) 39
FIGURE 11 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT 40
4 PREMIUM INSIGHTS 41
4.1 HUMAN MICROBIOME MARKET OVERVIEW 41
FIGURE 12 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH 41
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION AND COUNTRY (2023) 41
FIGURE 13 THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 41
4.3 HUMAN MICROBIOME MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 42
FIGURE 14 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS 44
5.2.1 DRIVERS 44
5.2.1.1 Collaborative efforts between microbiome industry and academia for microbiome research 44
5.2.1.2 Surging demand for personalized medicine 45
5.2.1.3 Rising awareness about importance of human microbiome 45
5.2.2 RESTRAINTS 46
5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes 46
5.2.3 OPPORTUNITIES 46
5.2.3.1 Increased collaboration of key players and small innovative companies to work on new microbiome technologies 46
TABLE 5 EXAMPLES OF COMPANY DEVELOPMENT 47
5.2.4 CHALLENGES 48
5.2.4.1 Slow patient adoption of microbiome-based therapies 48
5.2.4.2 Complexities involved in development of microbiome therapies 48
5.3 TECHNOLOGY ANALYSIS 49
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 51
FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 51
5.5 SUPPLY AND VALUE CHAIN ANALYSIS 52
5.5.1 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS 52
FIGURE 17 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS 52
5.5.2 VALUE CHAIN ANALYSIS OF HUMAN MICROBIOME MARKET 53
FIGURE 18 HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS 53
5.6 ECOSYSTEM ANALYSIS 54
FIGURE 19 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS 54
5.7 PORTER’S FIVE FORCES ANALYSIS 54
TABLE 6 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS 54
5.7.1 THREAT OF NEW ENTRANTS 54
5.7.2 THREAT OF SUBSTITUTES 54
5.7.3 BARGAINING POWER OF BUYERS 55
5.7.4 BARGAINING POWER OF SUPPLIERS 55
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 55
5.8 REGULATORY ANALYSIS 56
5.8.1 FDA APPROVALS 56
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
5.9 PRICING ANALYSIS 58
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT 58
5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS 58
5.10 KEY CONFERENCES AND EVENTS IN 2023 59
5.10.1 HUMAN MICROBIOME CONFERENCES (2023) 59
TABLE 12 HUMAN MICROBIOME CONFERENCES (2023) 59
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 60
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 60
FIGURE 20 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 60
5.11.2 HUMAN MICROBIOME MARKET: BUYING CRITERIA 60
FIGURE 21 KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS 60
6 HUMAN MICROBIOME MARKET, BY APPLICATION 61
6.1 INTRODUCTION 62
TABLE 13 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 62
6.2 THERAPEUTICS 62
6.2.1 AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET 62
TABLE 14 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023–2029 (USD MILLION) 64
TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 64
TABLE 16 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 64
TABLE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 65
6.3 DIAGNOSTICS 65
6.3.1 INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET 65
TABLE 18 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023–2029 (USD MILLION) 66
TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 66
TABLE 20 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 67
TABLE 21 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 67
7 HUMAN MICROBIOME MARKET, BY DISEASE 68
7.1 INTRODUCTION 69
TABLE 22 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 69
7.2 INFECTIOUS DISEASES 69
7.2.1 RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET 69
TABLE 23 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES 70
TABLE 24 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION) 71
TABLE 25 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 71
TABLE 26 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 71
TABLE 27 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 72
7.3 GASTROINTESTINAL DISEASES 72
7.3.1 SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET 72
TABLE 28 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION) 72
TABLE 29 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
TABLE 30 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
7.4 ENDOCRINE & METABOLIC DISORDERS 74
7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET 74
TABLE 32 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS 74
TABLE 33 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION) 75
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 75
TABLE 35 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 75
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 76
7.5 CANCER 76
7.5.1 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET 76
TABLE 37 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION) 77
TABLE 38 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 77
TABLE 39 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 77
TABLE 40 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 78
7.6 OTHER DISEASES 78
TABLE 41 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2029 (USD MILLION) 78
TABLE 42 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 78
TABLE 43 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 79
TABLE 44 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 79
8 HUMAN MICROBIOME MARKET, BY PRODUCT 80
8.1 INTRODUCTION 81
TABLE 45 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)) 81
8.2 DRUGS 81
8.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET 81
TABLE 46 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION) 82
TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 82
TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 82
TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 83
8.3 DIAGNOSTIC TESTS 83
8.3.1 GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET 83
TABLE 50 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023–2029 (USD MILLION) 84
TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 84
TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 85
TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 85
8.4 PROBIOTICS 85
8.4.1 GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY 85
TABLE 54 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2029 (USD MILLION) 86
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 86
TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 87
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 87
8.5 PREBIOTICS 87
8.5.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH 87
TABLE 58 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023–2029 (USD MILLION) 88
TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 88
TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 89
TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 89
8.6 OTHER PRODUCTS 89
TABLE 62 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2029 (USD MILLION) 90
TABLE 63 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 90
TABLE 64 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 90
TABLE 65 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 91
9 HUMAN MICROBIOME MARKET, BY TYPE 92
9.1 INTRODUCTION 93
TABLE 66 HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 93
9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) 93
9.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH 93
TABLE 67 HUMAN MICROBIOME MARKET FOR BCT/FMT, BY REGION, 2023–2029 (USD MILLION) 94
TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 94
TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 94
TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 95
9.3 PEPTIDES 95
9.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET 95
TABLE 71 HUMAN MICROBIOME MARKET FOR PEPTIDES, BY REGION, 2023–2029 (USD MILLION) 96
TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 96
TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 96
TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 97
9.4 LIVE BIOTHERAPEUTIC PRODUCTS 97
9.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET 97
TABLE 75 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023–2029 (USD MILLION) 98
TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 98
TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 98
TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 99
9.5 OTHER TYPES 99
TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY REGION, 2023–2029 (USD MILLION) 99
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
10 HUMAN MICROBIOME MARKET, BY REGION 101
10.1 INTRODUCTION 102
FIGURE 22 HUMAN MICROBIOME MARKET, BY REGION, 2023 VS. 2029 (USD MILLION) 102
TABLE 83 HUMAN MICROBIOME MARKET, BY REGION, 2023–2029 (USD MILLION) 102
10.2 NORTH AMERICA 103
FIGURE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT 104
TABLE 84 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 104
TABLE 85 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 105
TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 105
TABLE 87 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 105
10.2.1 US 106
10.2.1.1 Spike in research activities to drive market 106
TABLE 88 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 106
TABLE 89 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 107
TABLE 90 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 107
TABLE 91 US: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 107
10.2.2 CANADA 108
10.2.2.1 Rising prevalence of chronic diseases to boost microbiome research 108
TABLE 92 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 108
TABLE 93 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 108
TABLE 94 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 109
TABLE 95 CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 109
10.2.3 NORTH AMERICA: RECESSION IMPACT 109
10.3 EUROPE 110
TABLE 96 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 110
TABLE 97 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 111
TABLE 98 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 111
TABLE 99 EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 111
10.3.1 GERMANY 112
10.3.1.1 Rapid increase in government funding to propel market 112
TABLE 100 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 112
TABLE 101 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 112
TABLE 102 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 113
TABLE 103 GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 113
10.3.2 UK 113
10.3.2.1 Significant government investments in genomics research to propel growth 113
TABLE 104 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 114
TABLE 105 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 114
TABLE 106 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 114
TABLE 107 UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 115
10.3.3 FRANCE 115
10.3.3.1 Rise in microbiome sequencing startups to boost growth 115
TABLE 108 HUMAN MICROBIOME STARTUPS IN FRANCE 116
TABLE 109 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 116
TABLE 110 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 117
TABLE 111 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 117
TABLE 112 FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 117
10.3.4 REST OF EUROPE 118
TABLE 113 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 118
TABLE 114 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 118
TABLE 115 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 119
TABLE 116 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 119
10.3.5 EUROPE: IMPACT OF RECESSION 119
10.4 ASIA PACIFIC 120
FIGURE 24 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT 121
TABLE 117 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION) 121
TABLE 118 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 122
TABLE 119 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 122
TABLE 120 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 122
TABLE 121 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 123
10.4.1 CHINA 123
10.4.1.1 Increasing R&D investments to drive growth 123
TABLE 122 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 124
TABLE 123 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 124
TABLE 124 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 124
TABLE 125 CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 125

10.4.2 JAPAN 125
10.4.2.1 Growing geriatric population to present opportunities for market growth 125
TABLE 126 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 126
TABLE 127 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 126
TABLE 128 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 126
TABLE 129 JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 127
10.4.3 INDIA 127
10.4.3.1 Increasing prevalence of chronic diseases to support growth 127
TABLE 130 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 128
TABLE 131 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 128
TABLE 132 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 128
TABLE 133 INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 129
10.4.4 REST OF ASIA PACIFIC 129
TABLE 134 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 129
TABLE 135 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 130
TABLE 136 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 130
TABLE 137 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 130
10.4.5 ASIA PACIFIC: RECESSION IMPACT 131
10.5 REST OF THE WORLD 131
TABLE 138 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 131
TABLE 139 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 132
TABLE 140 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 132
TABLE 141 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 132
10.5.1 REST OF THE WORLD: RECESSION IMPACT 133
11 COMPETITIVE LANDSCAPE 134
11.1 INTRODUCTION 134
11.2 KEY STRATEGIES ADOPTED BY PLAYERS 134
FIGURE 25 HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 135

11.3 COMPANY EVALUATION QUADRANT 136
FIGURE 26 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (2022) 137
11.3.1 STARS 138
11.3.2 EMERGING LEADERS 138
11.3.3 PERVASIVE PLAYERS 138
11.3.4 PARTICIPANTS 138
11.4 COMPANY EVALUATION QUADRANT: START-UPS/SMES 139
11.4.1 PROGRESSIVE COMPANIES 139
11.4.2 STARTING BLOCKS 139
11.4.3 RESPONSIVE COMPANIES 139
11.4.4 DYNAMIC COMPANIES 139
FIGURE 27 HUMAN MICROBIOME MARKET: START-UPS/SMES EVALUATION QUADRANT (2022) 140
11.4.5 COMPETITIVE BENCHMARKING 141
11.4.5.1 Human microbiome market: Detailed list of start-ups/SMEs 141
TABLE 142 HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES 141
11.4.5.2 Human microbiome market: Competitive benchmarking of key players (start-ups/SMEs) 142
TABLE 143 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES) 142
11.5 COMPETITIVE SCENARIO AND TRENDS 142
TABLE 144 HUMAN MICROBIOME MARKET: DEALS 142
11.5.1 PRODUCT LAUNCHES 144
TABLE 145 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES 144
11.5.2 EXPANSIONS 144
TABLE 146 HUMAN MICROBIOME MARKET: EXPANSIONS 144
12 COMPANY PROFILES 145
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS 145
12.1.1 SERES THERAPEUTICS, INC. 145
TABLE 147 SERES THERAPEUTICS, INC.: COMPANY OVERVIEW 145
12.1.2 ENTEROME 148
TABLE 148 ENTEROME: COMPANY OVERVIEW 148
12.1.3 4D PHARMA PLC 151
TABLE 149 4D PHARMA: COMPANY OVERVIEW 151
FIGURE 29 4D PHARMA: COMPANY SNAPSHOT (2022) 151
12.1.4 INTERNATIONAL FLAVORS & FRAGRANCES, INC. 154
TABLE 150 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW 154
FIGURE 30 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022) 155

12.1.5 OPTIBIOTIX HEALTH PLC 157
TABLE 151 OPTIBIOTIX: COMPANY OVERVIEW 157
FIGURE 31 OPTIBIOTIX: COMPANY SNAPSHOT (2021) 158
12.1.6 FERRING PHARMACEUTICALS 162
TABLE 152 FERRING PHARMACEUTICALS: COMPANY OVERVIEW 162
12.1.7 SYNLOGIC, INC. 163
TABLE 153 SYNLOGIC, INC.: COMPANY OVERVIEW 163
FIGURE 32 SYNLOGIC, INC: COMPANY SNAPSHOT (2022) 163
12.1.8 SECOND GENOME INC. 165
TABLE 154 SECOND GENOME INC.: COMPANY OVERVIEW 165
12.1.9 VEDANTA BIOSCIENCES, INC. 167
TABLE 155 VEDANTA BIOSCIENCES: COMPANY OVERVIEW 167
12.1.10 YSOPIA BIOSCIENCE 169
TABLE 156 YSOPIA BIOSCIENCE: COMPANY OVERVIEW 169
12.1.11 FLIGHTPATH BIOSCIENCES, INC. 170
TABLE 157 FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW 170
12.1.12 FINCH THERAPEUTICS GROUP, INC. 171
TABLE 158 FINCH THERAPEUTICS: COMPANY OVERVIEW 171
FIGURE 33 FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022) 171
12.1.13 AOBIOME THERAPEUTICS 172
TABLE 159 AOBIOME THERAPEUTICS: COMPANY OVERVIEW 172
12.1.14 BIOGAIA 173
TABLE 160 BIOGAIA: COMPANY OVERVIEW 173
FIGURE 34 BIOGAIA: COMPANY SNAPSHOT (2021) 174
12.1.15 QUANTBIOME, INC. (DBA OMBRE) 177
TABLE 161 QUANTBIOME, INC.: COMPANY OVERVIEW 177
12.2 OTHER PLAYERS 178
12.2.1 VIOME LIFE SCIENCES, INC. 178
12.2.2 BIOHM HEALTH 178
12.2.3 DAYTWO 179
12.2.4 ALTAS BIOMED 179
12.2.5 BIONE VENTURES PRIVATE LIMITED 180
12.2.6 LUXIA SCIENTIFIC 180
12.2.7 METABIOMICS 181
12.2.8 SUN GENOMICS 181
12.2.9 SEED HEALTH 182
12.2.10 GNUBIOTICS SCIENCES 182
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX 183
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 186
13.2 CUSTOMIZATION OPTIONS 188
13.3 RELATED REPORTS 188
13.4 AUTHOR DETAILS 189


    お問合せフォーム

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com